Thibaut Quennesson followed pharmaceutical studies at the University of Lille and complementary courses in medicinal and organic chemistry. In 2019 he joined Dr. Stefan Schiesser (Aztrazeneca, Gothenburg) to work on the investigation of the synthesis and the in vitro properties of N-trifluoromethyl amines and azoles (J. Med. Chem. 2020, 63, 21, 13076–13089).
He obtained his Masters’ degree and joined the lab of Pr. Benoît Deprez (INSERM U1177, Institut de Pasteur de Lille, Faculté des sciences pharmaceutiques de Lille) to work on the design and synthesis of ERAP inhibitors for cancer and autoimmune diseases under the supervision of Pr. Rebecca Deprez-Poulain.
Since January 2021, he is doing his PhD under the supervision Pr. Serge Van Calenbergh at the Ghent University on the discovery of DXR inhibitors as anti-infectives agents.